Table 3

Univariate analysis of baseline and posttreatment variables adversely affecting PFS and OS

VariableHR95% CI
P
PFS     
    EMD 3.81 1.93 7.50 .000 
    Postinduction PET SUV > 4.2 3.44 1.32 8.98 .007 
    Post-ASCT PET SUV > 100% reduction 2.69 1.15 6.28 .022 
    < VGPR (best response) 2.29 1.17 4.50 .016 
    Baseline PET SUV > 4.2 2.19 1.28 3.73 .003 
    Del(17p) ± t(4;14) 2.17 1.36 3.47 .001 
    Baseline PET FLs > 3 1.80 1.11 2.91 .017 
    ISS stage II-III 1.74 1.03 2.95 .039 
OS     
    Relapse 9.31 2.78 31.16 .000 
    Post-ASCT PET SUV > 100% reduction 3.93 1.15 13.42 .029 
    EMD 3.91 1.55 9.88 .002 
    Postinduction PET SUV > 4.2 3.11 0.77 12.50 .09 
    < VGPR (best response) 2.74 1.03 7.32 .044 
    Baseline PET SUV > 4.2 2.62 1.14 5.99 .023 
    Del(17p) ± t(4;14) 2.60 1.32 5.13 .006 
VariableHR95% CI
P
PFS     
    EMD 3.81 1.93 7.50 .000 
    Postinduction PET SUV > 4.2 3.44 1.32 8.98 .007 
    Post-ASCT PET SUV > 100% reduction 2.69 1.15 6.28 .022 
    < VGPR (best response) 2.29 1.17 4.50 .016 
    Baseline PET SUV > 4.2 2.19 1.28 3.73 .003 
    Del(17p) ± t(4;14) 2.17 1.36 3.47 .001 
    Baseline PET FLs > 3 1.80 1.11 2.91 .017 
    ISS stage II-III 1.74 1.03 2.95 .039 
OS     
    Relapse 9.31 2.78 31.16 .000 
    Post-ASCT PET SUV > 100% reduction 3.93 1.15 13.42 .029 
    EMD 3.91 1.55 9.88 .002 
    Postinduction PET SUV > 4.2 3.11 0.77 12.50 .09 
    < VGPR (best response) 2.74 1.03 7.32 .044 
    Baseline PET SUV > 4.2 2.62 1.14 5.99 .023 
    Del(17p) ± t(4;14) 2.60 1.32 5.13 .006 

HR indicates hazard ratio; CI, confidence interval; PFS, progression-free survival; OS, overall survival; EMD, extramedullary disease; PET, positron emission tomography; SUV, standardized uptake value; ISS, international staging system; ASCT, autologous stem cell transplantation; VGPR, very good partial response; FL, focal lesion; del, deletion; and t, translocation.

View Large